New Zealand markets open in 6 hours 45 minutes

ImmunityBio, Inc. (IBRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.15+0.18 (+2.01%)
At close: 04:00PM EDT
9.07 -0.08 (-0.87%)
After hours: 07:59PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 6.19B
Enterprise value 6.66B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.48k
Price/book (mrq)N/A
Enterprise value/revenue 10.70k
Enterprise value/EBITDA -15.26

Trading information

Stock price history

Beta (5Y monthly) 0.04
52-week change 339.94%
S&P500 52-week change 322.38%
52-week high 310.53
52-week low 31.25
50-day moving average 35.55
200-day moving average 33.58

Share statistics

Avg vol (3-month) 36.89M
Avg vol (10-day) 320.12M
Shares outstanding 5677.04M
Implied shares outstanding 6677.04M
Float 8145.27M
% held by insiders 179.25%
% held by institutions 18.75%
Shares short (15 Apr 2024) 454.84M
Short ratio (15 Apr 2024) 412.1
Short % of float (15 Apr 2024) 439.03%
Short % of shares outstanding (15 Apr 2024) 48.10%
Shares short (prior month 15 Mar 2024) 453.25M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-60,792.80%

Management effectiveness

Return on assets (ttm)-52.11%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)622k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)90.40%
Gross profit (ttm)N/A
EBITDA -342.85M
Net income avi to common (ttm)-583.2M
Diluted EPS (ttm)-1.15
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)266.46M
Total cash per share (mrq)0.4
Total debt (mrq)883.68M
Total debt/equity (mrq)N/A
Current ratio (mrq)5.05
Book value per share (mrq)-0.88

Cash flow statement

Operating cash flow (ttm)-366.76M
Levered free cash flow (ttm)-234.66M